Vaccine‐Induced Anti‐ <scp>IgE</scp> Antibodies Neutralize Free <scp>IgE</scp> but Fail to Bind and Activate <scp>Mast Cell</scp> ‐Displayed <scp>IgE</scp>
In conclusion, the CuMV<sub>TT</sub>-Cε3-Cε4 vaccine induces high titers of anti-IgE IgGs that confer protection by neutralizing IgE through its glycan epitopes, without causing FcεRI cross-linking. Our results imply that an anti-IgE vaccine may represent a promising therapeutic strategy, offering effective protection while minimizing the risk of adverse reactions similar to the monoclonal antibody omalizumab.
Authors
- Monique Vogel (ORCID: https://orcid.org/0000-0002-5219-4033)
- Martin F. Bachmann (ORCID: https://orcid.org/0000-0003-4370-2099)
- Zahra Gharailoo (ORCID: https://orcid.org/0009-0006-5373-1300)
- Paul Engeroff (ORCID: https://orcid.org/0000-0002-3409-512X)
Institutions
- University of Bern (CH)
- University of Oxford (GB)
- Jenner Institute (GB)
Publication Details
- Journal
- Allergy
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1111/all.16530
- Citations
- 6
- Primary Topic
- Mast cells and histamine
- Type
- article
- Field-Weighted Citation Impact
- 4.78
Funders
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Novartis Stiftung für Medizinisch-Biologische Forschung